Share on StockTwits

OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff acquired 5,500 shares of OHR Pharmaceutical stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average cost of $10.25 per share, for a total transaction of $56,375.00. Following the purchase, the director now directly owns 122,166 shares of the company’s stock, valued at approximately $1,252,202. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

OHR Pharmaceutical (NASDAQ:OHRP) traded up 3.86% on Wednesday, hitting $10.22. The stock had a trading volume of 677,928 shares. OHR Pharmaceutical has a 1-year low of $4.20 and a 1-year high of $20.00. The stock has a 50-day moving average of $15.49 and a 200-day moving average of $10.38. The company’s market cap is $204.1 million.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) is a biotechnology rollup company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.